Drug Profile
Pelabresib - MorphoSys
Alternative Names: CPI-0610Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Constellation Pharmaceuticals
- Developer Constellation Pharmaceuticals; MorphoSys; The Leukemia & Lymphoma Society
- Class Amides; Antihaemorrhagics; Antineoplastics; Benzazepines; Chlorinated hydrocarbons; Oxazoles; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myelofibrosis
- Phase II Essential thrombocythaemia; Leukaemia; Myelodysplastic syndromes
- Phase I Haematological malignancies; Solid tumours
- Discontinued Lymphoma; Multiple myeloma
Most Recent Events
- 18 Mar 2024 Discontinued - Phase-I for Lymphoma (Second-line therapy or greater) in USA (PO) (MorphoSys pipeline, March 2024)
- 18 Mar 2024 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (PO) (MorphoSys pipeline, March 2024)
- 13 Mar 2024 Morphosys announces intention to submit NDA for pelabresib in combination with ruxolitinib to US FDA for Myelofibrosis in the middle of 2024